Symbols / NMRD
NMRD Chart
About
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 4.04K |
| Enterprise Value | 19.51M | Income | -10.65M | Sales | — |
| Book/sh | -0.62 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 36 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | inf | P/B | -0.00 | P/C | — |
| EV/EBITDA | -1.73 | EV/Sales | — | Quick Ratio | 0.02 |
| Current Ratio | 0.19 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.04 | EPS next Y | -0.44 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-02-12 09:00 | ROA | -81.19% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 40.35M |
| Shs Float | 12.43M | Short Float | 0.31% | Short Ratio | 0.30 |
| Short Interest | — | 52W High | 0.00 | 52W Low | 0.00 |
| Beta | -118.95 | Avg Volume | 2.31K | Volume | 500.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 7952874447175815627014144.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-4.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-21 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-07-17 | main | EF Hutton | Buy → Buy | $4 |
| 2023-03-30 | reit | EF Hutton | — → Buy | $6 |
| 2023-02-28 | main | EF Hutton | — → Buy | $6 |
| 2023-02-27 | main | HC Wainwright & Co. | — → Buy | $7 |
| 2022-08-19 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2022-03-29 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2021-12-02 | init | EF Hutton | — → Buy | $8 |
- PNM Resources Announces Sale of Renewable Joint Venture - PR Newswire ue, 26 Dec 2023 08
- Nemaura Medical touts clinical trial data for non-invasive glucose monitor - Drug Delivery Business Wed, 31 Jan 2018 08
- Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor - Proactive Investors Mon, 05 Nov 2018 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.02 | 0.05 |
| NormalizedEBITDA | -8.17M | -7.34M | -4.49M |
| TotalUnusualItems | 883.96K | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 883.96K | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.14M | -13.89M | -6.26M |
| ReconciledDepreciation | 444.18K | 229.81K | 98.08K |
| ReconciledCostOfRevenue | 1.55M | 344.30K | 0.00 |
| EBITDA | -7.29M | -7.34M | -4.49M |
| EBIT | -7.73M | -7.57M | -4.59M |
| NetInterestIncome | -6.41M | -6.67M | -2.01M |
| InterestExpense | 6.41M | 6.67M | 2.01M |
| NormalizedIncome | -15.03M | -13.89M | -6.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.14M | -13.89M | -6.26M |
| TotalExpenses | 8.69M | 8.07M | 4.59M |
| TotalOperatingIncomeAsReported | -9.60M | -7.57M | -4.59M |
| DilutedAverageShares | 24.88M | 23.38M | 22.28M |
| BasicAverageShares | 24.88M | 23.38M | 22.28M |
| DilutedEPS | -0.57 | -0.59 | -0.28 |
| BasicEPS | -0.57 | -0.59 | -0.28 |
| DilutedNIAvailtoComStockholders | -14.14M | -13.89M | -6.26M |
| NetIncomeCommonStockholders | -14.14M | -13.89M | -6.26M |
| NetIncome | -14.14M | -13.89M | -6.26M |
| NetIncomeIncludingNoncontrollingInterests | -14.14M | -13.89M | -6.26M |
| NetIncomeContinuousOperations | -14.14M | -13.89M | -6.26M |
| TaxProvision | 0.00 | -350.26K | -335.83K |
| PretaxIncome | -14.14M | -14.24M | -6.59M |
| OtherIncomeExpense | 883.96K | ||
| SpecialIncomeCharges | -980.04K | 0.00 | |
| ImpairmentOfCapitalAssets | 980.04K | 0.00 | |
| GainOnSaleOfSecurity | 1.86M | ||
| NetNonOperatingInterestIncomeExpense | -6.41M | -6.67M | -2.01M |
| InterestExpenseNonOperating | 6.41M | 6.67M | 2.01M |
| OperatingIncome | -8.62M | -7.57M | -4.59M |
| OperatingExpense | 7.14M | 7.73M | 4.59M |
| ResearchAndDevelopment | 1.54M | 1.56M | 1.55M |
| SellingGeneralAndAdministration | 5.60M | 6.17M | 3.03M |
| GeneralAndAdministrativeExpense | 5.60M | 6.17M | 3.03M |
| OtherGandA | 5.60M | 6.17M | 3.03M |
| GrossProfit | -1.48M | 159.61K | 0.00 |
| CostOfRevenue | 1.55M | 344.30K | 0.00 |
| TotalRevenue | 77.04K | 503.91K | 0.00 |
| OperatingRevenue | 77.04K | 503.91K | 0.00 |
| Line Item | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|
| OrdinarySharesNumber | 28.90M | 24.10M | 22.94M |
| ShareIssued | 28.90M | 24.10M | 22.94M |
| NetDebt | 9.93M | 1.44M | |
| TotalDebt | 20.03M | 19.19M | 24.92M |
| TangibleBookValue | -12.20M | -1.01M | 7.30M |
| InvestedCapital | 8.22M | 19.65M | 33.28M |
| WorkingCapital | -8.73M | -494.44K | 27.57M |
| NetTangibleAssets | -12.20M | -1.01M | 7.30M |
| CommonStockEquity | -11.81M | 466.08K | 8.36M |
| TotalCapitalization | -8.73M | 466.08K | 27.55M |
| TotalEquityGrossMinorityInterest | -11.81M | 466.08K | 8.36M |
| StockholdersEquity | -11.81M | 466.08K | 8.36M |
| GainsLossesNotAffectingRetainedEarnings | -959.26K | -122.32K | 135.57K |
| OtherEquityAdjustments | -959.26K | -122.32K | 135.57K |
| RetainedEarnings | -51.88M | -37.73M | -23.84M |
| AdditionalPaidInCapital | 40.99M | 38.30M | 32.04M |
| CapitalStock | 28.90K | 24.10K | 22.94K |
| CommonStock | 28.90K | 24.10K | 22.94K |
| TotalLiabilitiesNetMinorityInterest | 26.38M | 21.64M | 26.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.11M | 1.05M | 20.46M |
| NonCurrentDeferredLiabilities | 1.02M | 1.05M | 1.28M |
| NonCurrentDeferredRevenue | 1.02M | 1.05M | 1.28M |
| LongTermDebtAndCapitalLeaseObligation | 3.09M | 19.19M | |
| LongTermDebt | 3.09M | 19.19M | |
| CurrentLiabilities | 22.27M | 20.58M | 6.42M |
| OtherCurrentLiabilities | 3.82M | 440.20K | 180.55K |
| CurrentDeferredLiabilities | 123.64K | 259.26K | 103.47K |
| CurrentDeferredRevenue | 123.64K | 259.26K | 103.47K |
| CurrentDebtAndCapitalLeaseObligation | 16.94M | 19.19M | 5.73M |
| CurrentDebt | 16.94M | 19.19M | 5.73M |
| OtherCurrentBorrowings | 16.94M | 19.19M | 5.73M |
| PayablesAndAccruedExpenses | 1.38M | 694.74K | 402.49K |
| CurrentAccruedExpenses | 130.68K | 558.43K | 180.55K |
| Payables | 1.25M | 136.31K | 402.49K |
| DuetoRelatedPartiesCurrent | 920.78K | 0.00 | 148.79K |
| AccountsPayable | 326.64K | 136.31K | 253.69K |
| TotalAssets | 14.56M | 22.10M | 35.24M |
| TotalNonCurrentAssets | 1.03M | 2.01M | 1.26M |
| GoodwillAndOtherIntangibleAssets | 384.09K | 1.48M | 1.06M |
| OtherIntangibleAssets | 384.09K | 1.48M | 1.06M |
| NetPPE | 641.91K | 532.51K | 202.15K |
| AccumulatedDepreciation | -471.59K | -273.61K | -144.35K |
| GrossPPE | 1.11M | 806.12K | 346.50K |
| MachineryFurnitureEquipment | 1.11M | 806.12K | |
| CurrentAssets | 13.54M | 20.09M | 33.99M |
| OtherCurrentAssets | 357.93K | 495.06K | |
| PrepaidAssets | 909.67K | 0.00 | 1.18M |
| Inventory | 1.75M | 1.49M | 850.62K |
| FinishedGoods | 168.07K | 5.83K | |
| RawMaterials | 1.59M | 1.48M | |
| Receivables | 409.65K | 356.41K | 89.33K |
| DuefromRelatedPartiesCurrent | 0.00 | 101.30K | |
| TaxesReceivable | 409.65K | 255.11K | 89.33K |
| AccountsReceivable | 101.30K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 10.11M | 17.75M | 31.87M |
| CashAndCashEquivalents | 10.11M | 17.75M | 31.87M |
| CashFinancial | 10.11M | 17.75M | 31.87M |
| Line Item | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|
| FreeCashFlow | -8.99M | -7.46M | -6.83M |
| RepaymentOfDebt | -10.27M | -12.40M | -600.00K |
| IssuanceOfDebt | 4.70M | 0.00 | 25.00M |
| IssuanceOfCapitalStock | 8.39M | 3.12M | 15.75M |
| CapitalExpenditure | -539.22K | -956.48K | -836.44K |
| InterestPaidSupplementalData | 0.00 | 0.00 | |
| EndCashPosition | 10.11M | 17.75M | 31.87M |
| BeginningCashPosition | 17.75M | 31.87M | 106.11K |
| EffectOfExchangeRateChanges | -735.22K | -287.30K | 607.41K |
| ChangesInCash | -6.91M | -13.83M | 31.15M |
| FinancingCashFlow | 2.08M | -6.37M | 37.99M |
| CashFlowFromContinuingFinancingActivities | 2.08M | -6.37M | 37.99M |
| NetOtherFinancingCharges | -737.66K | -50.77K | -2.56M |
| ProceedsFromStockOptionExercised | 0.00 | 2.96M | 400.50K |
| NetCommonStockIssuance | 8.39M | 3.12M | 15.75M |
| CommonStockIssuance | 8.39M | 3.12M | 15.75M |
| NetIssuancePaymentsOfDebt | -5.57M | -12.40M | 24.40M |
| NetLongTermDebtIssuance | -5.57M | -12.40M | 24.40M |
| LongTermDebtPayments | -10.27M | -12.40M | -600.00K |
| LongTermDebtIssuance | 4.70M | 0.00 | 25.00M |
| InvestingCashFlow | -539.22K | -956.48K | -836.44K |
| CashFlowFromContinuingInvestingActivities | -539.22K | -956.48K | -836.44K |
| NetIntangiblesPurchaseAndSale | -27.88K | -391.07K | -663.76K |
| PurchaseOfIntangibles | -27.88K | -391.07K | -663.76K |
| NetPPEPurchaseAndSale | -376.17K | -481.72K | -90.73K |
| PurchaseOfPPE | -376.17K | -481.72K | -90.73K |
| CapitalExpenditureReported | -135.17K | -83.69K | -81.95K |
| OperatingCashFlow | -8.45M | -6.50M | -6.00M |
| CashFlowFromContinuingOperatingActivities | -8.45M | -6.50M | -6.00M |
| ChangeInWorkingCapital | -2.05M | -174.79K | -1.96M |
| ChangeInOtherWorkingCapital | -1.08M | ||
| ChangeInOtherCurrentLiabilities | 310.49K | 94.14K | |
| ChangeInPayablesAndAccruedExpense | -237.42K | 193.11K | -721.21K |
| ChangeInAccruedExpense | -427.75K | 310.49K | |
| ChangeInPayable | 190.33K | -117.38K | -721.21K |
| ChangeInAccountPayable | 190.33K | -117.38K | -39.91K |
| ChangeInPrepaidAssets | -17.41K | 519.35K | -767.05K |
| ChangeInInventory | -1.75M | -637.15K | -564.31K |
| ChangeInReceivables | 1.02M | -250.09K | |
| OtherNonCashItems | 6.42M | 6.67M | 2.01M |
| StockBasedCompensation | 0.00 | 220.92K | 113.17K |
| AssetImpairmentCharge | 2.46M | 0.00 | |
| DepreciationAmortizationDepletion | 444.18K | 229.81K | 98.08K |
| DepreciationAndAmortization | 444.18K | 229.81K | 98.08K |
| OperatingGainsLosses | -1.57M | 440.20K | |
| GainLossOnInvestmentSecurities | -1.57M | 440.20K | |
| GainLossOnSaleOfPPE | 0.00 | ||
| NetIncomeFromContinuingOperations | -14.14M | -13.89M | -6.26M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NMRD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|